Dyax announces positive results from phase 1b clinical trial of DX-2930
Dyax announced positive safety, pharmacokinetic, biomarker, and efficacy results from the Phase 1b clinical study of their investigational product, DX-2930. Dyax's DX-2930 is a fully human monoclonal antibody inhibitor of plasma kallikrein being developed for the prevention of HAE attacks. March 31, 2015